Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOPIN trial of PHP with or without ipilimumab + nivolumab in metastatic uveal melanoma
NL-OMON59189Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in intraocular melanoma comparing PHP alone with PHP + ipilimumab + nivolumab (2 arms). Primary endpoints: Safety and feasibility of PHP combined with ipilimumab and nivolumab and Progression-free survival at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON59189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59189.